Cargando…

Current status of autologous stem cell transplantation for multiple myeloma

More than 30 years after its introduction, autologous stem cell transplantation (ASCT) remains the standard of care for young patients with newly diagnosed multiple myeloma. Not only did the arrival of novel agents such as immunomodulatory drugs (IMiDs), proteasome inhibitors (PI) and monoclonal ant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Al Hamed, Rama, Bazarbachi, Abdul Hamid, Malard, Florent, Harousseau, Jean-Luc, Mohty, Mohamad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6453900/ https://www.ncbi.nlm.nih.gov/pubmed/30962422 http://dx.doi.org/10.1038/s41408-019-0205-9

Ejemplares similares

Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update
por: Bazarbachi, Abdul Hamid, et al.
Publicado: (2022)

Bortezomib, Lenalidomide and Dexamethasone as Induction Therapy Prior to Autologous Transplantation in Multiple Myeloma: The More Is Likely the Better
por: Mohty, Mohamad, et al.
Publicado: (2020)

Comprehensive Review of AL amyloidosis: some practical recommendations
por: Al Hamed, Rama, et al.
Publicado: (2021)

Allogeneic transplant for FLT3-ITD mutated AML: a focus on FLT3 inhibitors before, during, and after transplant
por: Bazarbachi, Abdul Hamid, et al.
Publicado: (2019)

Cardiac toxicities in multiple myeloma: an updated and a deeper look into the effect of different medications and novel therapies
por: El-Cheikh, Jean, et al.
Publicado: (2023)

Management of patients with multiple myeloma during the COVID-19 pandemic
por: Malard, Florent, et al.
Publicado: (2020)

New drugs before, during, and after hematopoietic stem cell transplantation for patients with acute myeloid leukemia
por: Mohty, Razan, et al.
Publicado: (2023)

Non-interventional Study Evaluating the Mobilization of Stem Cells by Plerixafor Before Salvage Autologous Stem Cell Transplant in Relapsed Multiple Myeloma (IFM-2015-03)
por: van de Wyngaert, Zoe, et al.
Publicado: (2023)

Current Advances in Multiple Myeloma: A Post International Myeloma Society (IMS 2022) Round Table Debate by the International Academy for Clinical Hematology (IACH)
por: Bahlis, Nizar J., et al.
Publicado: (2023)

Latest advances in the management of classical Hodgkin lymphoma: the era of novel therapies
por: Mohty, Razan, et al.
Publicado: (2021)

Maintenance therapy in multiple myeloma
por: Harousseau, Jean-Luc
Publicado: (2009)

Interleukin-22 in Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation
por: Lamarthée, Baptiste, et al.
Publicado: (2016)

COVID-19 in the context of autologous hematopoietic stem cell transplantation for a patient with autoimmune disease
por: Alsuliman, Tamim, et al.
Publicado: (2022)

Daratumumab prevents programmed death ligand‐1 expression on antigen‐presenting cells in de novo multiple myeloma
por: Stocker, Nicolas, et al.
Publicado: (2020)

New Insight for the Diagnosis of Gastrointestinal Acute Graft-versus-Host Disease
por: Malard, Florent, et al.
Publicado: (2014)

Posttransplant maintenance therapy in multiple myeloma: the changing landscape
por: Sengsayadeth, S, et al.
Publicado: (2017)

Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma without Cryopreservation
por: Al-Anazi, Khalid Ahmed
Publicado: (2012)

Update on the Role of Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
por: Tosi, P., et al.
Publicado: (2012)

Complete response after autologous stem cell transplant in multiple myeloma
por: Kumar, Lalit, et al.
Publicado: (2014)

Post-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple Myeloma
por: Al-Mansour, Zeina, et al.
Publicado: (2014)

Characteristics of exceptional responders to autologous stem cell transplantation in multiple myeloma
por: Paquin, Ashley, et al.
Publicado: (2020)

Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma
por: Yarlagadda, Lakshmi, et al.
Publicado: (2021)

Interrupted Identities: Autologous Stem Cell Transplant in Patients With Multiple Myeloma
por: Halpin, Sean N, et al.
Publicado: (2021)

Outcomes of autologous stem cell transplantation for multiple myeloma in Saudi Arabia
por: Abdrabou, Ahmed Kotb, et al.
Publicado: (2021)

Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma
por: Srour, Samer A., et al.
Publicado: (2021)

P-149: Immunogenicity of SARS-CoV-2 vaccine in patients with multiple myeloma
por: Malard, Florent, et al.
Publicado: (2021)

Impact of tandem autologous stem cell transplantation and response to transplant in the outcome of multiple myeloma
por: Bergantim, Rui, et al.
Publicado: (2012)

Sequential, Autologous Hematopoietic Stem Cell Transplant Followed by Renal Transplant in Multiple Myeloma
por: Bhowmik, D., et al.
Publicado: (2017)

CAR-T cell therapy in myeloma: hopes and hurdles
por: Harousseau, Jean Luc
Publicado: (2023)

Lenalidomide before and after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
por: Tuchman, S. A., et al.
Publicado: (2012)

Therapeutic effects of autologous hematopoietic stem cell transplantation in multiple myeloma patients
por: FU, CHENGCHENG, et al.
Publicado: (2013)

Autologous Stem Cell Transplantation in Multiple Myeloma with Renal Failure: Friend or Foe?
por: Zhong, Hongfei, et al.
Publicado: (2019)

Comparison of single and double autologous stem cell transplantation in multiple myeloma patients
por: Malkan, Umit Yavuz, et al.
Publicado: (2021)

Long-Term Responders After Autologous Stem Cell Transplantation in Multiple Myeloma
por: Oliver-Caldes, Aina, et al.
Publicado: (2022)

Experience of Autologous Stem Cell Transplant in Multiple Myeloma: The Patient and Caregiver Perspective
por: Hansen, Doris K, et al.
Publicado: (2023)

Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease
por: Mohty, Razan, et al.
Publicado: (2022)

Autologous Stem Cell Transplantation for Myeloma: Cytoreduction or an Immunotherapy?
por: Minnie, Simone A., et al.
Publicado: (2021)

Immunotherapy for Multiple Myeloma
por: Kröger, Nicolaus, et al.
Publicado: (2012)

Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma
por: Lee, Se Ryeon, et al.
Publicado: (2010)

Multiple Myeloma Involving Skin and Pulmonary Parenchyma after Autologous Stem Cell Transplantation
por: Yuan, Yuan, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_dvr90pduk99fpq3b94gp5ip131